2026-10-14T07:44:42Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33771202 2026-09-15T04:32:47Z category_393 portal_316 item_type_3 month_year_09_2026

Table 1_Cost-effectiveness analysis of pembrolizumab plus trastuzumab and chemotherapy as first-line treatment for HER2-positive gastric or gastroesophageal junction adenocarcinoma.docx Haoyu Yang (728452) Weihao Ge (6080207) Shuxian Jiang (32542) Xin Lan (422210) Xinting Du (24912127) Foetal Development and Medicine cost-effectiveness gastric/gastroesophageal junction adenocarcinoma HER2-positive pembrolizumab trastuzumab Objectives<p>The final analysis of KEYNOTE-811 demonstrated that pembrolizumab plus trastuzumab and chemotherapy significantly improved both overall survival (OS) and progression-free survival (PFS) compared to trastuzumab plus chemotherapy alone. Based on these latest findings, this study evaluated the cost-effectiveness of pembrolizumab plus trastuzumab and chemotherapy from the perspective of the Chinese healthcare system.​</p>Design<p>Using a partitioned survival model, this study compared quality-adjusted life years (QALYs), total costs, and incremental cost-effectiveness ratios (ICERs) between pembrolizumab plus trastuzumab and chemotherapy versus trastuzumab plus chemotherapy alone. Efficacy and safety data were derived from KEYNOTE-811, local databases, and relevant literature. To validate the robustness of the model results, sensitivity analyses were conducted. Additionally, subgroup analyses were conducted specifically for the patient population with PD-L1 expression ≥1%.​</p>Interventions<p>Pembrolizumab plus trastuzumab and chemotherapy.</p>Outcome measures<p>Total costs, life years, quality adjusted life years (QALYs), incremental QALYs and incremental cost-effectiveness ratio (ICER).</p>Results<p>In the intention-to-treat (ITT) population, pembrolizumab plus trastuzumab and chemotherapy demonstrated a gain of 0.56 QALYs compared to trastuzumab plus chemotherapy alone, with an additional cost of $322,653.47, resulting in an ICER of $571,997.42/QALY. In the PD-L1 ≥ 1 subgroup, the pembrolizumab combination arm showed a QALY improvement of 0.38, yielding an ICER of $1,178,714.74 per QALY.​</p>Conclusion<p>From the perspective of Chinese healthcare system, the addition of pembrolizumab to trastuzumab-chemotherapy as first-line therapy failed to demonstrate cost-effectiveness for HER2-positive gastric/gastroesophageal junction adenocarcinoma across both the ITT population and PD-L1 ≥ 1 subgroup.</p> 2026-09-15T04:32:47Z Dataset Dataset 10.3389/fmed.2026.1905243 https://figshare.com/articles/dataset/Table_1_Cost-effectiveness_analysis_of_pembrolizumab_plus_trastuzumab_and_chemotherapy_as_first-line_treatment_for_HER2-positive_gastric_or_gastroesophageal_junction_adenocarcinoma_docx/33771202 CC BY 4.0